


Supplementary Table 1. The quality of studies assessed by the revised Jadad or NOS.

Study	Randomization	Allocation concealment	Blinding	Dropout	Jadad score
Berg et al. ¹⁴	2	2	2	1	7
Liaw et al. ¹⁵	2	1	1	1	5
Fung et al. ¹⁶	2	1	2	1	6
Lim et al. ¹⁷	2	2	0	1	5
Yoo et al. ¹⁸	2	2	0	1	5

Study	Selection	Comparability	Outcomes	NOS score
Seto et al. ¹⁹	3	1	3	7
Lee et al. ²²	2	1	2	5
Lu et al. ²⁰	3	1	2	6
Choi et al. ²¹	3	1	2	6

Supplementary Figure 1. Funnel plots for some outcomes. A) 24-week virological suppression; B) 48-week virological suppression; C) HBV DNA reduction; D) HBeAg loss.



Supplementary Figure 2. Forest map of summary estimate for comparison of serum HBV DNA reduction between TDF-based combination therapy and monotherapy groups.

